Markus Raderer

18.2k total citations · 1 hit paper
324 papers, 11.9k citations indexed

About

Markus Raderer is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Markus Raderer has authored 324 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Pathology and Forensic Medicine, 164 papers in Oncology and 90 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Markus Raderer's work include Lymphoma Diagnosis and Treatment (164 papers), Neuroendocrine Tumor Research Advances (52 papers) and Chronic Lymphocytic Leukemia Research (47 papers). Markus Raderer is often cited by papers focused on Lymphoma Diagnosis and Treatment (164 papers), Neuroendocrine Tumor Research Advances (52 papers) and Chronic Lymphocytic Leukemia Research (47 papers). Markus Raderer collaborates with scholars based in Austria, Germany and United States. Markus Raderer's co-authors include Andreas Chott, Michael Hejna, Berthold Streubel, Werner Scheithauer, Barbara Kiesewetter, Stefan Wöhrer, Gabriela Kornek, Christoph Zielinski, Johannes Drach and Andrea Lamprecht and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Markus Raderer

310 papers receiving 11.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

2014 1.3k citations Martyn Caplin, Marianne Pavel et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Markus Raderer

Since Specialization

Citations

This map shows the geographic impact of Markus Raderer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Raderer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Raderer more than expected).

Fields of papers citing papers by Markus Raderer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Raderer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Raderer. The network helps show where Markus Raderer may publish in the future.

Co-authorship network of co-authors of Markus Raderer

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Raderer. A scholar is included among the top collaborators of Markus Raderer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Raderer. Markus Raderer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei 2025 ·Haematologica ·(unknown), (unknown), Gundula Rendl, Jan Marco Kern, Lenka Bašková, Daniel Neureiter, Thomas Melchardt, Markus Raderer, Richard Greil, Christian Pirich	0
2	Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study 2024 ·The Oncologist ·Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, (unknown), (unknown), (unknown), (unknown), Markus Raderer	4
3	Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial 2023 ·Infectious Agents and Cancer ·Maximilian J. Mair, (unknown), (unknown), Rainer Puhr, (unknown), Marlene Troch, Hannah Christina Puhr, Angelika M. Starzer, Ariane Steindl, (unknown), Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W. Prager, Wolfgang Lamm, Anna S. Berghoff, Barbara Kiesewetter, Markus Zeitlinger, Matthias Preusser, Markus Raderer	1
4	CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie 2023 ·Nuklearmedizin - NuclearMedicine ·(unknown), (unknown), Aleksander Kosmala, (unknown), Toru Higuchi, (unknown), Philipp E. Hartrampf, Samuel Samnick, Markus Raderer, (unknown), (unknown), Andreas K. Buck, (unknown), Rudolf A. Werner	1
5	The impact of COVID-19 and socioeconomic status on psychological distress in cancer patients 2023 ·International Journal of Clinical and Health Psychology ·Elisabeth L. Zeilinger, Matthias Knefel, (unknown), Jakob Pietschnig, Simone Lubowitzki, Matthias Unseld, Thorsten Füreder, Rupert Bartsch, Eva Katharina Masel, (unknown), (unknown), Barbara Kiesewetter, Sabine Zöchbauer‐Müller, Markus Raderer, Maria Theresa Krauth, Philipp B. Staber, Peter Valent, Alexander Gaiger	2
6	Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients 2022 ·International Journal of Clinical and Health Psychology ·Elisabeth L. Zeilinger, Ingo W. Nader, Wolfgang Wiedermann, Mencía R. Gutiérrez-Colosía, Matthias Unseld, Simone Lubowitzki, Markus Raderer, Philipp B. Staber, Peter Valent, Alexander Gaiger	8
7	The impact of COVID‐19 on cancer care of outpatients with low socioeconomic status 2022 ·International Journal of Cancer ·Elisabeth L. Zeilinger, Simone Lubowitzki, Matthias Unseld, (unknown), (unknown), Philipp B. Staber, Markus Raderer, Peter Valent, Sabine Zöchbauer‐Müller, Rupert Bartsch, Gerald W. Prager, Ulrich Jaeger, Alexander Gaiger	13
8	A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial 2021 ·BMC Cancer ·(unknown), Lisa Kaiser, (unknown), (unknown), Andreas Viardot, Peter Mӧller, Thomas F.E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, Barbara Kiesewetter, Christian Buske	5
9	CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication 2021 ·Blood ·Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Michael Weber, Barbara Kiesewetter, (unknown), Ingrid Simonitsch‐Klupp, Marcus Hacker, Asha Leisser, Lukas Nics, (unknown), Hans‐Juergen Wester, Alexander Haug	28
10	Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI 2020 ·Journal of Personalized Medicine ·Hossein Taghizadeh, Matthias Unseld, (unknown), Robert M. Mader, Leonhard Müllauer, Thorsten Fuereder, Markus Raderer, Maria Sibilia, Mir Alireza Hoda, Stefanie Aust, Stephan Polterauer, Wolfgang Lamm, Rupert Bartsch, Matthias Preusser, Alexandra Kautzky‐Willer, Gerald W. Prager	7
11	Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria 2020 ·International Journal of Endocrinology ·Gundula Rendl, (unknown), Alexander Becherer, (unknown), Christian Trummer, Markus Raderer, Wolfgang Hitzl, (unknown), H. J. Gallowitsch, Christian Pirich	26
12	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients 2015 ·Clinical Cancer Research ·Marius E. Mayerhoefer, Georgios Karanikas, Kurt Kletter, Helmut Prosch, Barbara Kiesewetter, Cathrin Skrabs, Edit Porpaczy, Michael Weber, (unknown), Christian Sillaber, Ulrich Jaeger, Ingrid Simonitsch‐Klupp, (unknown), Leonhard Müllauer, Werner Dolak, Julius Lukas, Markus Raderer	66
13	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas 2015 ·Medicine ·Ana‐Iris Schiefer, Christoph Kornauth, Ingrid Simonitsch‐Klupp, Cathrin Skrabs, Eva Katharina Masel, Berthold Streubel, Katrina Vanura, Karin Walter, (unknown), Dagmar Stoiber, Veronika Sexl, Markus Raderer, Andreas Chott, María Gomes da Silva, José Cabeçadas, Leonhard Müllauer, Ulrich Jäger, Edit Porpaczy	19
14	Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients 2014 ·Clinical Cancer Research ·Marius E. Mayerhoefer, Georgios Karanikas, Kurt Kletter, Helmut Prosch, Barbara Kiesewetter, Cathrin Skrabs, Edit Porpaczy, Michael Weber, Katja Pinker, Dominik Berzaczy, Martha Hoffmann, Christian Sillaber, Ulrich Jaeger, Leonhard Müllauer, Ingrid Simonitsch‐Klupp, Werner Dolak, Alexander Gaiger, (unknown), Julius Lukas, Markus Raderer	81
15	Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors breakdown → 2014 ·New England Journal of Medicine ·Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski	1286
16	Primary Follicular Lymphoma of the Duodenum Is a Distinct Mucosal/Submucosal Variant of Follicular Lymphoma: A Retrospective Study of 63 Cases 2011 ·Journal of Clinical Oncology ·(unknown), Berthold Streubel, Elisabeth Kretschmer‐Chott, Andreas Püspök, Ulrich Jäger, Christine Mannhalter, Markus Tiemann, German Ott, Wolfgang Fischbach, Peter Herzog, Gerhard Seitz, Manfred Stolte, Markus Raderer, Andreas Chott	152
17	EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT 2011 ·Gut ·A. Ruskoné-Fourmestraux, Wolfgang Fischbach, B.M.P. Aleman, Henk Boot, Ming‐Qing Du, Françis Mégraud, Carlos Montalbán, Markus Raderer, Antonella Savio, Andrew Wotherspoon, (unknown)	245
18	A phase II study of bortezomib in patients with MALT lymphoma 2009 ·Haematologica ·Marlene Troch, Constanze Jonak, Leonhard Müllauer, Andreas Püspök, Michael Formanek, W. Hauff, Christoph Zielinski, Andreas Chott, Markus Raderer	45
19	MALT lymphoma associated genetic aberrations occur at different frequencies in primary and secondary intestinal MALT lymphomas 2006 ·Gut ·Berthold Streubel, Gerhard Seitz, M Stolte, P. Birner, Andreas Chott, Markus Raderer	15
20	Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma 1999 ·British Journal of Cancer ·Werner Scheithauer, Gabriela Kornek, Markus Raderer, Michael Hejna, Julia Valencak, J. Miholiċ, E. Kovats, Fritz Lang, Martin Funovics, Evelyne Bareck, D. Depisch	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact